User login
Key clinical point: In adolescents and adults with eosinophilic esophagitis (EoE), 300 mg dupilumab per week was effective and well-tolerated regardless of prior exposure to swallowed topical corticosteroids (STC).
Major finding: At week 24, a significantly higher proportion of patients receiving dupilumab vs placebo with (>50% vs ≤5%; P < .0001) or without (>45% vs ≤25%; P < .05) prior exposure to STC achieved a peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high-power field, with the improvements being maintained till week 52. No new adverse events were reported.
Study details: This sub-group analysis of the phase 3 LIBERTY EoE TREET study included 321 patients with EoE who were randomly assigned to receive dupilumab or placebo for 24 weeks, after which 304 patients received dupilumab for 28 weeks additionally.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Seven authors declared being employees or stockholders of Regeneron Pharmaceuticals or Sanofi. The other authors declared ties with various sources, including Sanofi and Regeneron.
Source: Bredenoord AJ et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: A subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 2023 (Nov 27). doi: 10.1136/gutjnl-2023-330220
Key clinical point: In adolescents and adults with eosinophilic esophagitis (EoE), 300 mg dupilumab per week was effective and well-tolerated regardless of prior exposure to swallowed topical corticosteroids (STC).
Major finding: At week 24, a significantly higher proportion of patients receiving dupilumab vs placebo with (>50% vs ≤5%; P < .0001) or without (>45% vs ≤25%; P < .05) prior exposure to STC achieved a peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high-power field, with the improvements being maintained till week 52. No new adverse events were reported.
Study details: This sub-group analysis of the phase 3 LIBERTY EoE TREET study included 321 patients with EoE who were randomly assigned to receive dupilumab or placebo for 24 weeks, after which 304 patients received dupilumab for 28 weeks additionally.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Seven authors declared being employees or stockholders of Regeneron Pharmaceuticals or Sanofi. The other authors declared ties with various sources, including Sanofi and Regeneron.
Source: Bredenoord AJ et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: A subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 2023 (Nov 27). doi: 10.1136/gutjnl-2023-330220
Key clinical point: In adolescents and adults with eosinophilic esophagitis (EoE), 300 mg dupilumab per week was effective and well-tolerated regardless of prior exposure to swallowed topical corticosteroids (STC).
Major finding: At week 24, a significantly higher proportion of patients receiving dupilumab vs placebo with (>50% vs ≤5%; P < .0001) or without (>45% vs ≤25%; P < .05) prior exposure to STC achieved a peak esophageal intraepithelial eosinophil count of ≤6 eosinophils per high-power field, with the improvements being maintained till week 52. No new adverse events were reported.
Study details: This sub-group analysis of the phase 3 LIBERTY EoE TREET study included 321 patients with EoE who were randomly assigned to receive dupilumab or placebo for 24 weeks, after which 304 patients received dupilumab for 28 weeks additionally.
Disclosures: This study was funded by Sanofi and Regeneron Pharmaceuticals Inc. Seven authors declared being employees or stockholders of Regeneron Pharmaceuticals or Sanofi. The other authors declared ties with various sources, including Sanofi and Regeneron.
Source: Bredenoord AJ et al. Dupilumab demonstrated efficacy and was well tolerated regardless of prior use of swallowed topical corticosteroids in adolescent and adult patients with eosinophilic oesophagitis: A subgroup analysis of the phase 3 LIBERTY EoE TREET study. Gut. 2023 (Nov 27). doi: 10.1136/gutjnl-2023-330220